MEBIAS’ business model is comprised of partnering and advancing its own molecules into early clinical development. Six years since its founding, the company has validated its unique drug discovery, identified a novel preclinical mu-opioid candidate entering Phase 1 human clinical studies in 2022, and currently developing Sphingosine 1-phosphate receptor (S1PR1) agonists for the treatment of neuropathic pain.